Reckitt Benckiser’s record $1.4B opioid settlement a warning for drug companies
By 
Jaclyn Jaeger2019-07-15T17:56:00
Reckitt Benckiser Group will pay $1.4 billion to resolve a long-running federal investigation concerning the sales and marketing of the opioid addiction treatment drug Suboxone.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleFalse Claims Act-related settlements top $5.6B in 2021
False Claims Act settlements totaled more than $5.6 billion in the past federal fiscal year, the second-largest amount ever collected by the government in FCA actions in one year, according to the Department of Justice.
-
ArticleCompliance ramifications of proposed $26B opioid deal for pharma industry
Three major drug distributors and drugmaker Johnson & Johnson reached a proposed $26 billion multistate agreement for their alleged roles in fueling the nationwide opioid epidemic. The settlement imparts compliance lessons on the pharmaceutical industry at large.
-
ArticleMcKinsey to pay $573M for role in opioid epidemic
McKinsey & Company reached a $573 million settlement with 49 state attorneys general and the District of Columbia related to consulting services it provided to pharmaceutical companies that directly contributed to the opioid epidemic.
More from Regulatory Enforcement
-
ArticleTeledyne fined $1.5M for supplying obsolete parts to Navy
Teledyne will pay more than $1.5 million to settle allegations it supplied electronic parts to the Navy that deviated from specifications, a violation of the False Claims Act (FCA). But its cooperation with prosecutors earned it a credit, according to the U.S. Department of Justice (DOJ).
-
ArticleTungston rod importer pays $54.4M to settle DOJ tariff fraud allegations
An industrial products distributor has agreed to pay $54.4 million to settle allegations, first made by a whistleblower, that it evaded tariffs and violated the federal False Claims Act.
-
ArticleTariff evasion enforcement: The new FCPA
Companies that import goods into the United States will face heightened enforcement scrutiny for attempted acts of customs fraud, including tariff evasion, under the Trump administration. Thus, chief compliance officers and in-house counsel face a new kind of pressure to ensure they are mitigating risk in this area.